Acute Leukaemia: Types, Symptoms and How It Is Treated

Acute leukaemia is one of the few cancers that behaves like an emergency. Where most malignancies develop over months or years, acute leukaemia can take a person from apparently well to critically ill in a matter of weeks — and, unusually among cancers, that speed cuts both ways: it is also among the diseases where prompt intensive treatment produces cure rather than control.

This guide covers what the disease is, how the two main types differ, which presentations are medical emergencies, how diagnosis is established, what modern treatment involves, and what the realistic outlook is for different groups. It is written to help patients and families understand what is happening, not to guide treatment — acute leukaemia is managed in hospital by haematology teams from the day of diagnosis.

🩸 What is happening in the bone marrow

Blood cells are produced in the bone marrow from stem cells that mature through a series of stages. In acute leukaemia, a cell early in that sequence acquires genetic changes that lock it in an immature state — a blast — while removing the normal signals that stop it dividing. The blasts multiply, fill the marrow, and crowd out production of everything else.

That crowding explains the entire clinical picture. Falling red cells produce anaemia: fatigue, pallor, breathlessness. Falling normal white cells leave the person unable to fight infection. Falling platelets produce bruising and bleeding. The blasts themselves spill into the bloodstream and can infiltrate the liver, spleen, lymph nodes, gums, skin and central nervous system.

The word acute is not a description of severity but of cell maturity: acute leukaemias involve immature blasts and progress rapidly, while chronic leukaemias involve more mature cells and evolve over years. Diagnosis conventionally requires 20% or more blasts in the marrow or blood, though certain genetic abnormalities establish the diagnosis at lower counts.

🔠 The two main types

Acute leukaemia divides according to which cell line the malignant clone arose from, and the distinction determines treatment entirely.

Within each type, genetic subgroups matter more than the broad category. Some abnormalities predict excellent response to standard treatment; others indicate a need for transplantation. This is why treatment is not decided until the genetic workup returns, except where the situation is too urgent to wait.

📋 How it presents

Symptoms develop over days to weeks and reflect marrow failure rather than a lump or a mass.

• Fatigue, pallor and breathlessness on minimal exertion — from anaemia, frequently the first thing noticed.
• Fever and recurrent or unusual infections — from the absence of functioning neutrophils.
• Easy bruising, petechiae, nosebleeds, bleeding gums, heavy periods — from low platelets.
• Bone and joint pain, particularly in children, from marrow expansion — sometimes mistaken for growing pains or arthritis.
• Swollen lymph nodes, enlarged liver or spleen, more typical of the lymphoblastic type.
• Weight loss, night sweats, loss of appetite.
• Gum swelling or skin infiltration, characteristic of certain myeloid subtypes.

Individually each of these has commoner explanations, which is why the diagnosis is frequently made when a blood count ordered for fatigue returns markedly abnormal. That full blood count is the single most important test in the whole pathway, and it is cheap and universally available.

🚨 The four emergencies

Several complications kill quickly and are managed before or alongside the leukaemia itself.

Febrile neutropenia is the emergency families most need to recognise, because it happens at home between hospital visits. A temperature of 38 degrees or above in someone receiving chemotherapy is an emergency requiring immediate attendance, regardless of how well the person otherwise appears. Waiting to see whether it settles is the mistake that costs lives.

🔬 How the diagnosis is established

The pathway moves quickly and involves several layers, each answering a different question.

Full blood count and blood film raise the suspicion, showing anaemia, abnormal white cell counts, low platelets and circulating blasts. Bone marrow aspiration and trephine biopsy confirm it, usually taken from the back of the pelvis under local anaesthetic.

The marrow sample then goes through three separate analyses. Immunophenotyping by flow cytometry identifies which cell line the blasts belong to, separating lymphoblastic from myeloid disease. Cytogenetics examines chromosomes for translocations and other abnormalities that define prognostic groups. Molecular testing identifies specific mutations, several of which now have drugs targeting them directly.

Additional tests include a lumbar puncture to check for central nervous system involvement, particularly in lymphoblastic disease; imaging where organ infiltration is suspected; and baseline cardiac and organ function testing before treatment that can affect the heart, liver and kidneys.

💊 Treating acute lymphoblastic leukaemia

Treatment is prolonged and structured in phases, and the structure is what produces the high cure rates in children.

Induction aims to clear detectable disease and restore normal marrow function, typically over four to six weeks with a combination of agents including corticosteroids, vincristine and asparaginase. Consolidation follows, using intensive blocks to eliminate residual disease. Maintenance then continues for two to three years with lower-intensity oral treatment — commonly mercaptopurine with methotrexate — because shortening this phase increases relapse.

Throughout, central nervous system prophylaxis is given, since leukaemic cells hide in the CNS where most chemotherapy penetrates poorly. This is delivered as intrathecal chemotherapy injected into the spinal fluid, and it is one of the innovations that transformed outcomes.

Where the Philadelphia chromosome is present, a tyrosine kinase inhibitor such as imatinib or dasatinib is added, converting a formerly poor-prognosis subgroup into one that responds well.

🧬 Treating acute myeloid leukaemia

Historically, treatment meant intensive chemotherapy combining cytarabine with an anthracycline over seven days, followed by consolidation courses. That regimen remains standard for patients fit enough to tolerate it.

The major recent change concerns everyone else. Many patients with AML are elderly or have other illnesses that make intensive chemotherapy unsurvivable, and for decades those patients received little more than supportive care. The combination of venetoclax with a hypomethylating agent changed that substantially, producing meaningful remission rates in patients previously considered untreatable.

Alongside this, targeted drugs now address specific mutations: inhibitors for FLT3, for IDH1 and IDH2, and antibody-drug conjugates for CD33-positive disease. Molecular testing at diagnosis determines which apply, which is why treatment decisions wait for those results where the clinical situation permits.

🏥 Stem cell transplantation

Allogeneic transplantation replaces the patient marrow with stem cells from a donor, after chemotherapy or radiotherapy has eliminated the existing marrow. Its power comes partly from the conditioning treatment and partly from the donor immune cells recognising and attacking residual leukaemia.

It is reserved for patients whose disease carries high relapse risk, or who have relapsed and achieved a second remission, because it carries substantial risks of its own: graft-versus-host disease, serious infection during the period without immunity, and organ toxicity. The decision balances the risk of the leukaemia returning against the risk of the procedure, and it is one of the more difficult conversations in medicine.

🛡️ Supportive care, which does much of the saving

A substantial share of the improvement in survival over recent decades came not from better chemotherapy but from better support during it.

• Transfusion support — red cells for anaemia, platelets to prevent bleeding while the marrow recovers.
• Infection prevention and rapid treatment — antimicrobial prophylaxis, central line care, and immediate broad-spectrum antibiotics at the first fever.
• Growth factors to shorten the period of neutropenia in selected situations.
• Tumour lysis prevention with hydration and drugs that lower uric acid before treatment begins.
• Nutrition, mouth care and antiemetics, which determine whether a patient can complete the planned treatment.
• Fertility preservation, discussed before treatment starts where possible, since several agents affect future fertility.
• Psychological and social support for a diagnosis that arrives without warning and upends a family within days.

📈 What the outlook actually is

Prognosis varies more within acute leukaemia than between most other cancers, and averages mislead badly. Three factors dominate: the type, the genetic subgroup, and the age and fitness of the patient.

Childhood lymphoblastic leukaemia is among the great successes of modern medicine, with long-term survival above 90% in current protocols — a transformation from a uniformly fatal disease within living memory. Adult lymphoblastic leukaemia does less well, though immunotherapies including bispecific antibodies and CAR-T cell therapy have improved options in relapsed disease considerably.

Acute myeloid leukaemia remains harder. Younger patients with favourable genetics can be cured with chemotherapy alone; older patients with adverse genetics face a difficult outlook, though targeted agents and venetoclax-based combinations have improved what was previously available. Age matters here more than in almost any other malignancy, because it determines what treatment a person can survive.

🏷️ About medication and this catalogue

Acute leukaemia is treated with intravenous chemotherapy, targeted agents, transfusions and transplantation, delivered in hospital under specialist supervision. It cannot be treated with medicines ordered online, and no part of this article should be read as suggesting otherwise.

Two drugs held in the oncology category do appear in leukaemia protocols in specific roles — methotrexate features in maintenance and central nervous system treatment of lymphoblastic disease, and hydroxyurea is used to reduce very high white cell counts. Both are prescribed, dosed and monitored by a haematology team as part of a protocol, with regular blood testing; neither is something a patient starts independently.

❓ Frequently asked questions

📑 Sources and editorial

• World Health Organization classification of haematolymphoid tumours — diagnostic criteria and genetic subgroups
• NCCN and ESMO clinical practice guidelines for acute lymphoblastic and acute myeloid leukaemia
• Published trial evidence on venetoclax combinations, FLT3 and IDH inhibitors, and immunotherapy in relapsed disease
• Guidance on febrile neutropenia, tumour lysis syndrome and management of acute promyelocytic leukaemia
• Population survival data for childhood and adult acute leukaemia from national cancer registries
• RXshop Editorial Team — reviewed by Emily Chen, MD, MPH, Internal Medicine